摘要
目的探究急性心力衰竭患者采用多巴酚丁胺注射液与左西孟旦治疗的疗效及对其心功能的影响。方法80例急性心力衰竭患者,根据治疗方法不同分为对照组和观察组,每组40例。对照组给予多巴酚丁胺注射液治疗,观察组给予左西孟旦治疗。比较两组患者治疗前后心功能[每搏输出量(SV)、心脏指数(CI)、左心室射血分数(LVEF)]水平、治疗效果、不良反应发生情况。结果治疗后,两组患者SV、LVEF、CI水平均高于治疗前,且观察组患者的SV(45.8±5.9)ml、LVEF(39.4±5.1)%、CI(2.6±0.8)L/(min·m^(2))均高于对照组的(41.3±5.2)ml、(35.6±4.8)%、(2.3±0.5)L/(min·m^(2)),差异均具有统计学意义有(P<0.05)。观察组治疗总有效率95.0%高于对照组的77.5%,不良反应发生率7.5%低于对照组的25.0%,差异具有统计学意义(P<0.05)。结论与多巴酚丁胺注射液治疗相比,将左西孟旦应用急性心力衰竭患者的治疗中,心功能水平可以得到显著改善,不良反应率降低,疗效满意,应用价值较高。
Objective To investigate the effect of levosimendan and dobutamine injection in the treatment of acute heart failure and its influence on cardiac function.Methods A total of 80 patients with acute heart failure were divided into control group and observation group according to different treatment methods,with 40 cases in each group.The control group was treated with dobutamine injection,and the observation group was treated with levosimendan.Both groups were compared in terms of cardiac function[stroke volume(SV),cardiac index(CI),left ventricular ejection fraction(LVEF)],therapeutic effects,and incidence of adverse reactions before and after treatment.Results After treatment,the levels of SV,LVEF,and CI of the two groups were higher than those of this group before treatment,and the SV(45.8±5.9)ml,LVEF(39.4±5.1)%,CI(2.6±0.8)L/(min·m^(2))of the observation group were higher than(41.3±5.2)ml,(35.6±4.8)%,(2.3±0.5)L/(min·m^(2))of the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment 95.0% of the observation group was higher than 77.5% of the control group,and the incidence of adverse reactions 7.5% was lower than 25.0% of the control group.All the differences were statistically significant(P<0.05).Conclusion Compared with dobutamine injection therapy,the use of levosimendan in patients with acute heart failure can significantly improve the level of cardiac function and lower the incidence of adverse reactions,and it has satisfied efficacy and higher application value.
作者
于庆伟
YU Qing-wei(Yingkou Huajun Hospital,Yingkou 115007,China)
出处
《中国现代药物应用》
2022年第2期117-119,共3页
Chinese Journal of Modern Drug Application